RESUMEN
Solution-phase, parallel-synthesis techniques were used to optimize a series of nonbasic NK-1 antagonists, resulting in the identification of (R)-26, an orally bioavailable compound with subnanomolar potency.
Asunto(s)
Antagonistas del Receptor de Neuroquinina-1 , Relación Estructura-ActividadRESUMEN
The characterization of a novel series of NPY-1 receptor antagonists derived from the 4-methylbenzimidazole 4 is described. Appropriate substitution on the piperidyl nitrogen of 4 led to systematic increases in Y-1 receptor affinity, to approximately 50-fold, and to the discovery of the importance of a second basic substituent.
Asunto(s)
Bencimidazoles/química , Bencimidazoles/farmacología , Receptores de Neuropéptido Y/antagonistas & inhibidores , Línea Celular , Proteínas Recombinantes/antagonistas & inhibidores , Relación Estructura-ActividadAsunto(s)
Indoles/síntesis química , Indoles/farmacología , Receptores de Neuropéptido Y/antagonistas & inhibidores , Animales , Relación Dosis-Respuesta a Droga , Ingestión de Alimentos/efectos de los fármacos , Humanos , Ratones , Ensayo de Unión Radioligante , Receptores de Neuropéptido Y/clasificación , Receptores de Neuropéptido Y/metabolismo , Relación Estructura-ActividadRESUMEN
The selective neurokinin (NK)-1 antagonist LY303870 has high affinity and specificity for human and guinea pig brain NK-1 receptors labeled with 125I-substance P. It has approximately 15- to 30-fold lower affinity for rat and mouse brain NK-1 receptors, consistent with previously reported species differences in the affinities of nonpeptide antagonists for NK-1 receptors. In vivo, LY303870 blocked the characteristic, caudally directed, biting and scratching response elicited by intrathecal administration of the selective NK-1 agonist Ac-[Arg6,Sar9,Met(O2)11]substance P6-11 in conscious mice. The potentiation of the tail-flick response elicited by intrathecal administration of the NK-1 agonist [Sar9,Met(O2)11]substance P in rats was also selectively blocked by LY303870. When tested in a model of persistent nociceptive activation induced by tissue injury (the formalin test), LY303870 blocked licking behavior in the late phase of the formalin test, in a dose-dependent manner. After oral administration of 10 mg/kg, the blockade of the late-phase licking behavior was evident for at least 24 hr. Ex vivo binding studies in guinea pigs showed that orally administered LY303870 potently inhibited binding to central and peripheral NK-1 receptors labeled with 125I-substance P. This inhibition was long-lasting, consistent with other in vivo activities. LY306155, the opposite enantiomer of LY303870, was less active in all of the functional assays. In rodents, LY303870 did not exhibit any neurological, motor, cardiovascular, gastrointestinal or autonomic side effects at doses of < or = 50 mg/kg p.o. Thus, LY303870 is a potent, centrally active, NK-1 antagonist in vivo, with long-lasting oral activity.
Asunto(s)
Indoles/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Dolor , Fragmentos de Péptidos/farmacología , Piperidinas/farmacología , Sustancia P/análogos & derivados , Animales , Sinergismo Farmacológico , Electrochoque , Formaldehído , Cobayas , Humanos , Inyecciones Espinales , Masculino , Ratones , Ratones Endogámicos , Actividad Motora/efectos de los fármacos , Fragmentos de Péptidos/administración & dosificación , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/agonistas , Reflejo de Sobresalto/efectos de los fármacos , Especificidad de la Especie , Médula Espinal/efectos de los fármacos , Médula Espinal/fisiología , Sustancia P/administración & dosificación , Sustancia P/farmacologíaRESUMEN
LY303870 is a competitive, high affinity NK-1 receptor antagonist. It was tested in the trigeminal stimulation-induced neurogenic dural inflammation model of migraine. The neurogenic inflammation theory of migraine pain proposes that substance P, acting through NK-1 receptors, causes dural inflammation which enhances migraine pain. LY303870 administration potently inhibited neurogenic dural inflammation as measured by plasma protein extravasation caused by electrical stimulation of the trigeminal ganglion in guinea pigs. It was active in this model when administered via intravenous, oral or inhalation routes. LY306155, the enantiomer of LY303870 with lower affinity for the NK-1 receptor, was much less potent than LY303870 in this model. LY303870, at oral doses of 1, 10 and 100 microg/kg, produced a long, dose-dependent inhibition of dural inflammation, demonstrating a suitable duration of action for a potential use in acute migraine and migraine prophylaxis.
Asunto(s)
Indoles/farmacología , Trastornos Migrañosos/metabolismo , Antagonistas del Receptor de Neuroquinina-1 , Piperidinas/farmacología , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Duramadre/efectos de los fármacos , Duramadre/metabolismo , Estimulación Eléctrica , Cobayas , Masculino , Estereoisomerismo , Sumatriptán/farmacologíaRESUMEN
BACKGROUND: The Cooperative Hernia Study assessed postoperative pain in a prospective trial as part of a larger study looking at the recurrence rate and other morbidity of the Bassini, McVay, and Shouldice repairs. METHODS: Patients were randomized to one of three surgical hernia repairs. Patients were seen in follow-up at 6, 12, and 24 months and were assessed for the presence of pain, numbness, paresthesia, and recurrence. RESULTS: Three hundred fifteen patients were seen in follow-up, with 276 seen at the 2-year mark. At 1 year, 62.9% of patients had groin or inguinal pain and 11.9% of patients had moderate to severe pain; 53.6% had pain and 10.6% of patients continued to report moderate to severe pain 2 years postoperatively. The predictors for long-term postoperative pain were as follows: absence of a visible bulge before the operation (p < 0.001); presence of numbness in the surgical area postoperatively (p < 0.05); and patient requirement of more than 4 weeks out of work postoperatively (p < 0.004). Three distinct chronic pains were identified. The most common and most severe pain was somatic, localized to the common ligamentous insertion to the public tubercle. The second was neuropathic and was referable to the ilioinguinal or genitofemoral nerve distribution. This was likely because of injury to the genitofemoral nerves, either at surgery or subsequently by encroachment of scar. The third pain was visceral, ejaculatory pain. Twenty-four percent of patients had postoperative numbness at 2 years, independent of the type of repair. Numbness was most common in the distribution of cutaneous branches of the ilioinguinal and iliohypogastric nerves. CONCLUSION: Pain or numbness are common late sequelae of traditional external surgical hernia repairs. Strategies need to be developed to reduce the risk of these complications.
Asunto(s)
Hernia Inguinal/cirugía , Dolor Postoperatorio/epidemiología , Adulto , Estudios de Seguimiento , Humanos , Dimensión del Dolor , Estudios ProspectivosRESUMEN
Early structure-activity studies on racemic tryptophan ester and amide NK-1 antagonists 5-7 led to the discovery that the potency of the series could be markedly increased by moving the carbonyl function in these molecules to an off-chain position as in the 3-aryl-1,2-diacetamidopropane 9. Further medicinal chemistry incorporating this change resulted in the discovery of a novel series of highly potent aryl amino acid derived NK-1 antagonists of the R stereoisomeric series (IC50's = 100 pM to > 5 microM). Compounds in this series were shown to be competitive antagonists using an in vitro NK-1 smooth muscle assay, and this data correlated well with observed human NK-1 binding affinities. Two of these agents, (R)-25 and (R)-32, blocked intrathecal NK-1 agonist-driven [Ac-[Arg6,Sar9,Met(O2)11]- substance P 6-11 (Ac-Sar9)] nociceptive behavior in mice. Both compounds potently blocked the neurogenic dural inflammation following trigeminal ganglion stimulation in the guinea pig after intravenous administration. Further, upon oral administration in this model, (R)-32 was observed to be very potent (ID50 = 91 ng/kg) and have a long duration of action (> 8 h at 1 micrograms/kg). Compound (R)-32, designated LY303870, is currently under clinical development as an NK-1 antagonist with a long duration of action.
Asunto(s)
Amidas/farmacología , Ésteres/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Amidas/química , Analgésicos/química , Analgésicos/farmacología , Animales , Estimulación Eléctrica , Ésteres/química , Cobayas , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Espectrometría de Masas , Ratones , Ratas , Especificidad de la Especie , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
LY303870 [(R)-1-[N-(2-methoxybenzyl)acetylamino]-3-(1H-indol-3-yl)-2-[N-(2-(4- (piperidin-1-yl)piperidin-1-yl)acetyl)amino]propane] is a new, potent and selective nonpeptide neurokinin-1 (NK-1) receptor antagonist. LY303870 bound selectively and with high affinity to human peripheral (Ki = 0.15 nM) and central (Ki = 0.10 nM) NK-1 receptors. LY303870 inhibited [125I]substance P (SP) binding to guinea pig brain homogenates with similar affinity; however, it had approximately 50-fold lesser affinity for rat NK-1 sites. The less active enantiomer, LY306155 [(S)-1-[N-(2-methoxybenzyl)acetylamino]-3-(1H-indol-3-yl)-2-[N-(2-(4- (piperidin-1-yl)piperidin-1-yl)acetyl)amino]-propane], was 1,000- to 15,000-fold less potent in all the species examined. LY303870 antagonized in vitro NK-1 receptor effects as demonstrated by blockade of SP-stimulated phosphoinositide turnover in UC-11 MG human astrocytoma cells (Ki = 1.5 nM) and interleukin-6 secretion from U-373 MG human astrocytoma cells (Ki = 5 nM). In addition, LY303870 inhibited SP-induced rabbit vena cava contractions (pA2 = 9.4) with high (50,000-fold) selectivity vs. NK-2 or NK-3 receptor-mediated responses. In vivo, LY303870 inhibited [Sar9,Met(O2)11]-SP induced guinea pig bronchoconstriction (ED50 = 75 micrograms/kg i.v.) and pulmonary microvascular leakage in the bronchi (ED50 = 12.8 micrograms/kg i.v.) and trachea (ED50 = 18.5 micrograms/kg i.v.). Therefore, LY303870 is a potent and selective NK-1 receptor antagonist in vitro and in vivo. The use of LY303870 will facilitate a better understanding of NK-1 receptors in physiological processes.
Asunto(s)
Indoles/farmacología , Piperidinas/farmacología , Receptores de Neuroquinina-1/efectos de los fármacos , Sustancia P/antagonistas & inhibidores , Resistencia de las Vías Respiratorias/efectos de los fármacos , Animales , Unión Competitiva , Bronquios/irrigación sanguínea , Permeabilidad Capilar/efectos de los fármacos , Células Cultivadas , Cobayas , Humanos , Fosfatos de Inositol/metabolismo , Interleucina-6/metabolismo , Masculino , Músculo Liso Vascular/efectos de los fármacos , Oligopéptidos/farmacología , Conejos , Ratas , Receptores de Neuroquinina-1/metabolismo , Sustancia P/análogos & derivados , Sustancia P/metabolismo , Tráquea/irrigación sanguínea , Vasodilatadores/farmacologíaRESUMEN
Tracheo-esophageal (T-E) fistulas secondary to blunt chest trauma are extremely uncommon. Once the diagnosis is confirmed, surgical correction is indicated as spontaneous healing rarely occurs. Should a barium esophagram demonstrate a persistent T-E fistula postoperatively, we suggest that in the absence of clinical or radiological evidence of mediastinal or pulmonary infection, a conservative treatment regimen may be considered in an attempt to resolve the fistula without surgical intervention. Conservative management should be abandoned and surgery indicated if mediastinitis or recurrent aspiration pneumonias occur, or the fistula fails to heal within a four to six week period.
Asunto(s)
Traumatismos Torácicos/complicaciones , Fístula Traqueoesofágica/terapia , Heridas no Penetrantes/complicaciones , Adulto , Nutrición Enteral , Humanos , Masculino , Cuidados Posoperatorios , Tráquea/cirugía , Fístula Traqueoesofágica/etiologíaAsunto(s)
Receptores de Neurotransmisores/antagonistas & inhibidores , Sustancia P/metabolismo , Animales , Unión Competitiva , Compuestos de Bifenilo/metabolismo , Compuestos de Bifenilo/farmacología , Bovinos , Pollos , Cobayas , Humanos , Ratones , Quinuclidinas/metabolismo , Quinuclidinas/farmacología , Conejos , Ratas , Receptores de Neuroquinina-1 , Receptores de Neurotransmisores/clasificación , Receptores de Neurotransmisores/metabolismo , Especificidad de la EspecieRESUMEN
Two members of a new class of non-peptide antagonists of substance P, (+-)-cis-3-(2-methoxybenzylamino)-2-benzhydrylquinuclidine [(+/-)-CP-96,345; I] and (+-)-cis-3-(2-chlorobenzylamino)-2-benzhydrylquinuclidine [II], were tested for their ability to antagonize neurokinin-induced contractions of the rabbit cava and jugular veins (NK-1), the rabbit pulmonary artery (NK-2) and the rat portal vein (NK-3 system). Compound 1 is the most potent NK-1 receptor antagonist identified until now; its apparent affinity (pA2 = 9.52) is at least two log units higher than those of other NK-1 antagonists. Compound II is less active. Both compounds have been found to be almost inactive as NK-2 and NK-3 antagonists and should, therefore, be considered as selective for the NK-1 receptor. The new compounds have no direct myotropic effects and are specific for neurokinin (NK-1) receptors since they do not affect the myotropic effects of angiotensin, noradrenaline and bradykinin in the rabbit cava and jugular veins.